Related Experiment Video
Updated: Mar 18, 2026
06:29
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
31.3K
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
Antonio M Risitano1, Serena Marotta1
1Hematology, Department of Clinical Medicine and Surgery; Federico II University, Naples, Italy.
Seminars in Immunology
|June 28, 2016
Summary
Anti-complement therapies, like eculizumab, have revolutionized treatment for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. New complement inhibitors targeting C3 and specific pathways offer improved efficacy for various complement-mediated anemias.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Anti-complement agents represent a significant advancement in treating complement-mediated diseases.
- Eculizumab transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
- Understanding of complement cascade's role in disease pathophysiology has evolved with extensive clinical experience.
Purpose of the Study:
- To review current and emerging complement inhibition strategies for complement-mediated anemias.
- To identify promising therapeutic approaches for specific complement-mediated anemias.
- To address the evolving landscape of complement-targeted therapies beyond PNH and aHUS.
Main Methods:
- Literature review of current and investigational anti-complement agents.
- Analysis of complement cascade pathways involved in anemias.
- Synthesis of clinical data on eculizumab and emerging therapies.
Main Results:
- Eculizumab has established new treatment paradigms for PNH and aHUS.
- New strategies include alternative anti-C5 agents, broad-spectrum anti-C3 agents, and pathway-specific inhibitors.
- Targeted inhibitors aim to prevent early pathogenic complement activation in diseases like antibody-mediated anemias and PNH/aHUS.
Conclusions:
- Complement inhibition is a rapidly advancing field with significant potential for various anemias.
- Next-generation therapies aim to enhance efficacy and address unmet clinical needs.
- Future research will focus on optimizing complement inhibition for diverse complement-mediated hematologic disorders.
Related Concept Videos
01:01Hypersensitivity Reactions: Cytolytic Reactions
91
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
91
01:27Complement System
12.0K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
12.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:23Antimicrobial Proteins
15.2K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
15.2K
01:25Inhibitors of Bacterial Protein Synthesis
14
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
14
01:30The Electron Transport Chain
21.0K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
21.0K